Bavituximab

Drug Profile

Bavituximab

Alternative Names: 3G4; Anti-phosphatidylserine monoclonal antibody 3G4; Anti-phospholipid monoclonal antibody 3G4; Anti-PS MAb 3G4; Monoclonal antibody 3G4; Tarvacin

Latest Information Update: 19 Jul 2017

Price : $50

At a glance

  • Originator Peregrine Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Immunovaccine; Massachusetts General Hospital; National Comprehensive Cancer Network; Peregrine Pharmaceuticals; University of Arizona; University of Texas Southwestern Medical Center
  • Class Adjuvants; Antineoplastics; Antivirals; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Immunostimulants; Phosphatidylserine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Glioblastoma
  • Phase I/II Hepatocellular carcinoma
  • Preclinical Brain cancer; Solid tumours
  • Suspended Breast cancer; Malignant melanoma; Pancreatic cancer; Rectal cancer
  • No development reported Hepatitis C; HIV infections; Viral haemorrhagic fevers
  • Discontinued Influenza virus infections; Prostate cancer

Most Recent Events

  • 14 Jul 2017 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins plans a phase II trial for progressive recurrent Head and neck cancer (Metastatic disease, Combination therapy) in combination with pembrolizumab in the second half of 2017
  • 07 Jul 2017 Peregrine Pharmaceuticals terminates a phase II/III trial for Breast cancer (Combination therapy, First-line therapy, Metastatic disease) in USA, Germany and Spain (NCT02651610)
  • 18 Jun 2017 Phase-II clinical trials in Glioblastoma (Combination therapy, Newly diagnosed) in USA (IV) (NCT03139916)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top